Characteristics of Symptomatic Intracranial Hemorrhage in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulant Therapy

OBJECTIVES: The first non-vitamin K antagonist oral anticoagulant (NOAC) introduced to the market in Japan was dabigatran in March 2011, and three more NOACs, rivaroxaban, apixaban, and edoxaban, have since become available. Randomized controlled trials of NOACs have revealed that intracranial hemor...

Descripción completa

Detalles Bibliográficos
Autores principales: Akiyama, Hisanao, Uchino, Kenji, Hasegawa, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501739/
https://www.ncbi.nlm.nih.gov/pubmed/26171862
http://dx.doi.org/10.1371/journal.pone.0132900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501739/
https://www.ncbi.nlm.nih.gov/pubmed/26171862
http://dx.doi.org/10.1371/journal.pone.0132900

Ejemplares similares